版本:
中国

Lonza to replace Actelion in Swiss blue-chip index -stock exchange

ZURICH, April 24 Drug ingredients maker Lonza will replace biotech company Actelion in Switzerland's blue-chip SMI stock index, the Swiss stock exchange said on Monday.

The change will take effect on May 3, Switzerland's SIX exchange said in a statement.

U.S. healthcare giant Johnson & Johnson is buying Actelion in a $30 billion all-cash deal. Analysts had considered Lonza the favourite to replace Actelion ahead of the likes of construction chemicals specialist Sika and hearing aid maker Sonova. (Reporting by Joshua Franklin; Editing by Adrian Croft)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐